{"organizations": [], "uuid": "e581faa73c0a738da9f6da715bd7c317123d9285", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180402.html", "section_title": "Archive News &amp; Video for Monday, 02 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-puma-biotechnology-nerlynx-include/brief-puma-biotechnology-nerlynx-included-as-recommended-treatment-option-in-nccn-clinical-practice-guidelines-idUSFWN1RF07K", "country": "US", "domain_rank": 408, "title": "BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.998, "site_type": "news", "published": "2018-04-02T21:09:00.000+03:00", "replies_count": 0, "uuid": "e581faa73c0a738da9f6da715bd7c317123d9285"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-puma-biotechnology-nerlynx-include/brief-puma-biotechnology-nerlynx-included-as-recommended-treatment-option-in-nccn-clinical-practice-guidelines-idUSFWN1RF07K", "ord_in_thread": 0, "title": "BRIEF-Puma Biotechnology ‍Nerlynx Included As Recommended Treatment Option In NCCN Clinical Practice Guidelines", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "puma biotechnology inc", "sentiment": "negative"}, {"name": "brief-puma biotechnology ‍nerlynx", "sentiment": "neutral"}, {"name": "eikon", "sentiment": "none"}, {"name": "ccn", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 2 (Reuters) - Puma Biotechnology Inc:\n* ‍NERLYNX INCLUDED AS RECOMMENDED TREATMENT OPTION IN NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY CENTRAL NERVOUS SYSTEM CANCERS\n* NCCN GUIDELINES INCLUDE NERLYNX IN COMBINATION WITH CAPECITABINE/ PACLITAXEL AS TREATMENT OPTIONS WITH BREAST CANCER BRAIN METASTASES​ Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-02T21:09:00.000+03:00", "crawled": "2018-04-03T16:12:47.017+03:00", "highlightTitle": ""}